Today we broke ground on our new $700M facility in Holly Springs, NC—Genentech’s first East Coast site. This 700K-sq-ft hub will support next-gen metabolic medicines and create 1,900+ jobs, strengthening U.S. innovation in biotech.

#Breaking: At #ASRS2025, we’re sharing results from our latest ophthalmology research, including data from our long-term, five-year study in people with wet age-related macular degeneration. Read the press release here:

What do you want to know?.

#Breaking: At AAIC, we’re presenting new data in #Alzheimers, underscoring our commitment to advancing the science in this disease. Learn More:

#Breaking: At #18ICML, we’re presenting data from our Phase III trial revealing how our novel combination therapy helped reduce the risk of disease progression for people living with large B-cell #lymphoma (#LBCL) in an outpatient setting. Learn more:

#Breaking: Today we announced we will advance our investigational medicine in early #ParkinsonsDisease into Phase III development. Learn more:

#Breaking at #ASCO25: We will present Phase III data, also published in @TheLancet, for ES-SCLC, offering a potential option for this aggressive cancer. Learn more:

#Breaking: We’re presenting new survival data for PIK3CA-mutated HR+, HER2- advanced #breastcancer at #ASCO25, also published in #NEJM. Read about the results here:

#Breaking: We’re excited to share two-year data from our investigational BTK inhibitor for people with relapsing multiple sclerosis (RMS) presented at this year’s #CMSC2025 meeting. Learn more about the results here:

At #ASCO25, we will present two-year follow-up data from our Phase III study that reinforces the potential of a CD20xCD3 bispecific antibody combined with chemotherapy in relapsed or refractory diffuse large B-cell #lymphoma. Learn more:

#Breaking: The @US_FDA has approved our treatment in a new indication for #DiabeticRetinopathy (DR). Learn more about how this treatment offers a new alternative to the standard of care for people with DR:

#Breaking: This #ESMOBreast25, we are excited to present ten-year follow-up data reinforcing the potential benefit of our treatment for HER2-positive early-stage breast cancer. Learn more:

#Breaking: @NEJM published a detailed analysis of positive Phase III data for.our influenza treatment and household #influenza transmission. Learn more:#PublicHealth #Flu

#Breaking: We’re presenting new data at #ADPD2025 showcasing advancements in our #Alzheimers research for the millions of people living with Alzheimer’s disease. Learn more:

ICYMI: Our supplemental Biologics License Application for our anti-CD20 monoclonal antibody for lupus nephritis treatment was accepted by the @US_FDA. Learn more:

ICYMI: The @US_FDA recently approved our clot-dissolving agent for the treatment of acute ischemic stroke (AIS) in adults. Read more:

#Breaking: The @US_FDA accepted our supplemental Biologics License Application for our medicine to treat #LupusNephritis based on Phase III data showing superiority over the current standard of care. Read more here:

The @US_FDA approved our clot-dissolving agent for acute ischemic stroke in adults—the first FDA-approved #stroke medicine in nearly 30 years. This approval reinforces our long-standing dedication to advancing stroke care for patients.

#Breaking: This #AAAAI25, we’re proud to present two late-breaking oral presentations featuring new Phase III data on our medicine for patients with food allergies. Learn more:

ICYMI: The first and only spinal muscular atrophy (#SMA) tablet has been granted approval by the FDA. Learn more: